ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells

Biochemical Pharmacology

Volumn 71, Issue 4, 2006, Pages 479-485

  Giannelli, Gianluigi ^a,c   Azzariti, Amalia ^b   Sgarra, Concetta ^a   Porcelli, Letizia ^b   Antonaci, Salvatore ^a   Paradiso, Angelo ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Biological therapies; Extracellular matrix proteins; Hepatocellular carcinoma; Invasion; Laminin 5; Proliferation; Vascular endothelial growth factor receptor; ZD6474

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KALININ; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SCLEROPROTEIN; VANDETANIB;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL ADHESION MOLECULES; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOPRECIPITATION; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; PIPERIDINES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS;

EID: 30444451162     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.11.005     Document Type: Article

References (38)

1. J.B. Wong, G.M. McQuillan, J.G. McHutchison, and T. Poynard Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 2000 1562 1569
2. M. Colombo, G. Kuo, Q.L. Choo, M.F. Donato, E. Del Ninno, and M.A. Tommasini Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma [see comments] Lancet 2 1989 1006 1008
3. J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219
4. E. Gunsilius, J. Tschmelitsch, M. Eberwein, H. Schwelberger, G. Spizzo, and C.M. Kahler In vivo release of vascular endothelial growth factor from colorectal carcinomas Oncology 62 2002 313 317
5. M. Klagsbrun, and P.A. D'Amore Regulators of angiogenesis Annu Rev Physiol 53 1991 217 239
6. D.R. Robinson, Y.M. Wu, and S.F. Lin The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
7. R. Yamaguchi, H. Yano, Y. Nakashima, S. Ogasawara, K. Higaki, and J. Akiba Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues Oncol Rep 7 2000 725 729
8. T. Shimamura, S. Saito, K. Morita, T. Kitamura, M. Morimoto, and T. Kiba Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens J Gastroenterol Hepatol 15 2000 640 646
9. A.L. Thomas, B. Morgan, J. Drevs, C. Unger, B. Wiedenmann, and U. Vanhoefer Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584 Semin Oncol 30 2003 32 38
10. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, and J.A. Jackson ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
11. F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, and D. Vitagliano Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 2003 1546 1556
12. J.V. Heymach ZD6474 - clinical experience to date Br J Cancer 92 Suppl. 1 2005 S14 S20
13. H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, and K. Yanase Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development J Hepatol 41 2004 97 103
14. G. Giannelli, and S. Antonaci Biological and clinical relevance of Laminin-5 in cancer Clin Exp Metastasis 18 2001 439 443
15. G. Giannelli, E. Fransvea, C. Bergamini, F. Marinosci, and S. Antonaci Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma Clin Cancer Res 9 2003 3684 3691
16. N. Koshikawa, G. Giannelli, V. Cirulli, K. Miyazaki, and V. Quaranta Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5 J Cell Biol 148 2000 615 624
17. B. Felding-Habermann, E. Fransvea, T.E. O'Toole, L. Manzuk, B. Faha, and M. Hensler Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells Clin Exp Metastasis 19 2002 427 436
18. G. Giannelli, C. Bergamini, E. Fransvea, F. Marinosci, V. Quaranta, and S. Antonaci Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion Lab Invest 81 2001 613 627
19. G. Giannelli, J. Falk-Marzillier, O. Schiraldi, W.G. Stetler-Stevenson, and V. Quaranta Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5 Science 277 1997 225 228
20. A. Albini, Y. Iwamoto, H.K. Kleinman, G.R. Martin, S.A. Aaronson, and J.M. Kozlowski A rapid in vitro assay for quantitating the invasive potential of tumor cells Cancer Res 47 1987 3239 3245
21. J.M. Xu, A. Azzariti, G. Colucci, and A. Paradiso The effect of gefitinib (Iressa ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines Cancer Chemother Pharmacol 52 2003 442 448
22. N. Magne, J.L. Fischel, C. Tiffon, P. Formento, A. Dubreuil, and N. Renee Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil Br J Cancer 89 2003 585 592
23. G. Tortora, R. Caputo, V. Damiano, D. Melisi, R. Bianco, and G. Fontanini Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin Cancer Res 9 2003 1566 1572
24. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653 660
25. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
26. M. Shibuya Structure and function of VEGF/VEGF-receptor system involved in angiogenesis Cell Struct Funct 26 2001 25 35
27. M.J. Karkkainen, and T.V. Petrova Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 19 2000 5598 5605
28. K.B. Reddy, S.M. Nabha, and N. Atanaskova Role of MAP kinase in tumor progression and invasion Cancer Metastasis Rev 22 2003 395 403
29. E. Viala, and J. Pouyssegur Regulation of tumor cell motility by ERK mitogen-activated protein kinases Ann N Y Acad Sci 1030 2004 208 218
30. G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci, and A. Paradiso Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 2004 1964 1969
31. S. Schenk, E. Hintermann, M. Bilban, N. Koshikawa, C. Hojilla, and R. Khokha Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution J Cell Biol 161 2003 197 209
32. M.P. Morelli, T. Cascone, T. Troiani, F. De Vita, M. Orditura, and G. Laus Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann Oncol 16 Suppl. 4 2005 iv61 iv68
33. B. Nicholson, K. Gulding, M. Conaway, S.R. Wedge, and D. Theodorescu Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach Clin Cancer Res 10 2004 8728 8734
34. F. Carlomagno, and M. Santoro Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer J Chemother 16 Suppl. 4 2004 49 51
35. A.J. Ryan, and S.R. Wedge ZD6474 - novel inhibitor of VEGFR and EGFR tyrosine kinase activity Br J Cancer 92 Suppl. 1 2005 S6 S13
36. K.J. Williams, B.A. Telfer, S. Brave, J. Kendrew, L. Whittaker, and I.J. Stratford ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
37. C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, and F. De Vita Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor Clin Cancer Res 11 2005 1268 1276
38. M. Schmitt, A. Horbach, R. Kubitz, A. Frilling, and D. Haussinger Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion J Hepatol 41 2004 274 283